QC6352
Based on 11 publication(s) in Google Scholar
QC6352 is an orally active KDM4 inhibitor with anti-tumor and anti-proliferative activity. QC6352 has in vivo inhibitory effects on PDX models of breast and colon cancer and reduces the number of chemoresistant cell populations. QC6352 inhibits KDM4 different isoforms with IC50s of 104 nM (KDM4A), 56 nM (KDM4B), 35 nM (KDM4C), and 104 nM (KDM4D), respectively. QC6352 has moderate inhibitory activity against KDM5 with an IC50 of 750 nM (KDM5B).
For research use only. We do not sell to patients.
- Purity: 99.13%
- CAS No.: 1851373-36-8
- Formula: C24H25N3O2
- Molecular Weight:387.47
-
Storage:
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocol
- Purity & Documentation
- References
-
Help & FAQs
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Orally Active Compound Library
HY-L061
-
Chemical Probe Library
HY-L063
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Transcription Factor-Targeted Library
HY-L090
-
Targeted Diversity Library
HY-L099
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Multi-Target Compound Library
HY-L176
-
Bioactive Compound Library Max
HY-L181
-
Epigenetics Compound Library Mini
HY-L005M
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) QC6352
More- Nat Commun. 2026 Feb 12;17(1):1214. [Abstract]
- Mol Cell. 2021 May 20;81(10):2148-2165.e9. [Abstract]
- Acta Pharmacol Sin. 2022 Feb;43(2):457-469. [Abstract]
- J Med Chem. 2024 Mar 28;67(6):4525-4540. [Abstract]
- RSC Med Chem. 2025 Jul 1. [Abstract]
- Clin Exp Med. 2025 Nov 25;26(1):33. [Abstract]
- BMC Bioinformatics. 2026 Feb 19.
- bioRxiv. 2025 Sep 16:2025.09.16.676586. [Abstract]
- bioRxiv. 2025 Feb 5:2025.01.31.635709. [Abstract]
- bioRxiv. 2024 Sep 16:2024.09.16.613328. [Abstract]
- bioRxiv. 2022 May 14.491739.
Biological Activity
|
KDM4 |
KDM5B 750 nM (IC50) |
KDM4A 104 nM (IC50) |
KDM4B 56 nM (IC50) |
KDM4C 35 nM (IC50) |
KDM4D 104 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Breast carcinoma cell | IC50 |
5 nM
Compound: 6; QC6352
|
Cytotoxicity against HER2-positive patient-derived breast cancer organoid model BR0869f after 5 days by Celltiter-Glo luminescent cell viability assay
Cytotoxicity against HER2-positive patient-derived breast cancer organoid model BR0869f after 5 days by Celltiter-Glo luminescent cell viability assay
|
[PMID: 28835804] |
| Colon carcinoma cell | IC50 |
13 nM
Compound: 6; QC6352
|
Cytotoxicity against patient-derived colon cancer organoid model SU60 after 96 to 168 hrs by Celltiter-Glo luminescent cell viability assay
Cytotoxicity against patient-derived colon cancer organoid model SU60 after 96 to 168 hrs by Celltiter-Glo luminescent cell viability assay
|
[PMID: 28835804] |
| IMR-90 | EC50 |
>30000 nM
Compound: 6; QC6352
|
Cytotoxicity against human IMR90 cells
Cytotoxicity against human IMR90 cells
|
[PMID: 28835804] |
| KYSE-150 cell line | EC50 |
3.5 nM
Compound: 6; QC6352
|
Antiproliferative activity against human KYSE-150 cells after 168 hrs by 5-bromo-2'-deoxyuridine thymidine incorporation assay
Antiproliferative activity against human KYSE-150 cells after 168 hrs by 5-bromo-2'-deoxyuridine thymidine incorporation assay
|
[PMID: 28835804] |
| KYSE-150 cell line | EC50 |
3.5 nM
Compound: 14; QC6352
|
Antiproliferative activity against human KYSE-150 cells after 168 hrs by 5-bromo-2'-deoxyuridine thymidine incorporation assay
Antiproliferative activity against human KYSE-150 cells after 168 hrs by 5-bromo-2'-deoxyuridine thymidine incorporation assay
|
[PMID: 35838529] |
QC6352 is a potent KDM4C inhibitor with an IC50 of 35±8 nM[1]. In a concentration-dependent manner QC6352 dramatically reduces the sphere-forming capacity of BCSC1 and BCSC2. QC6352 blocks proliferation and self-renewal of BCSCs. As shown by western blot analysis the protein levels of (Epidermal growth factor receptor) EGFR are reduced in both BCSC1 and BCSC2 upon treatment with QC6352[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 1851373-36-8
-
Appearance Solid
-
Molecular Weight 387.47
-
Formula C24H25N3O2
-
Color Light yellow to yellow
-
SMILES
O=C(C1=C(NC[C@@H]2CCCC3=C2C=CC(N(C)C4=CC=CC=C4)=C3)C=NC=C1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Human iPSC-based Modeling of Pulmonary Fibrosis Reveals p300/CBP Inhibition Suppresses Alveolar Transitional Cell State. [Abstract]2026 Feb 12;17(1):1214. PMID: 41680175 -
Mol Cell
Targeting KDM4A epigenetically activates tumor-cell-intrinsic immunity by inducing DNA replication stress. [Abstract]2021 May 20;81(10):2148-2165.e9. PMID: 33743195 -
Acta Pharmacol Sin
2022 Feb;43(2):457-469. PMID: 33850273 -
J Med Chem
Focused Screening Identifies Different Sensitivities of Human TET Oxygenases to the Oncometabolite 2-Hydroxyglutarate. [Abstract]2024 Mar 28;67(6):4525-4540. PMID: 38294854 -
RSC Med Chem
2025 Jul 1. PMID: 40656835 -
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164 -
-
bioRxiv
2025 Sep 16:2025.09.16.676586. PMID: 41000952 -
bioRxiv
Heterochromatin fidelity is a therapeutic vulnerability in lymphoma and other human cancers. [Abstract]2025 Feb 5:2025.01.31.635709. PMID: 39975048 -
bioRxiv
Distinct H3K9me3 heterochromatin maintenance dynamics govern different gene programs and repeats in pluripotent cells. [Abstract]2024 Sep 16:2024.09.16.613328. PMID: 39345615 -
Solvent & Solubility
DMSO : 16.67 mg/mL (43.02 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 1.67 mg/mL (4.31 mM); Clear solution
This protocol yields a clear solution of ≥ 1.67 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.67 mg/mL (4.31 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.67 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (16.7 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 10 mg/mL (25.81 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 2 years; -20°C, 1 year (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocol
Cells are detached by Accutase and counted. 1×103 single BCSC1 and BCSC2 cells are seeded as triplicates in 50% Matrigel into individual wells of 24-well ultra-low attachment plates in serum-free MSC medium. After 7 days, spheres over 50 μm diameter are counted for QC6352- and QC6688-treated and control cells and spheres over 20 μm diameter are counted for paclitaxel-treated and control cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Mice: When tumors reach a palpable size of 3 mm3, mice are treated with vehicle (control) or QC6352. The inhibitor is administered daily to mice via oral gavage at 10 mg/kg. Control animals receive vehicle only. Animals are monitored twice weekly for weight and tumor growth[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Purity & Documentation
-
Data Sheet (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year (protect from light). When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5808 mL | 12.9042 mL | 25.8084 mL | 64.5211 mL |
| 5 mM | 0.5162 mL | 2.5808 mL | 5.1617 mL | 12.9042 mL | |
| 10 mM | 0.2581 mL | 1.2904 mL | 2.5808 mL | 6.4521 mL | |
| 15 mM | 0.1721 mL | 0.8603 mL | 1.7206 mL | 4.3014 mL | |
| 20 mM | 0.1290 mL | 0.6452 mL | 1.2904 mL | 3.2261 mL | |
| 25 mM | 0.1032 mL | 0.5162 mL | 1.0323 mL | 2.5808 mL | |
| 30 mM | 0.0860 mL | 0.4301 mL | 0.8603 mL | 2.1507 mL | |
| 40 mM | 0.0645 mL | 0.3226 mL | 0.6452 mL | 1.6130 mL |
QC6352 Related Classifications
HY-104048 Related Classifications
Powered by Bioz